Cutaneous Squamous Cell Carcinoma Clinical Trial
Official title:
A Phase 2 Peri-Operative Study of Treatment With Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Patients With Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)
This study is researching an investigational drug called REGN2810, also known as cemiplimab, when combined with another investigational drug called REGN3767, also known as fianlimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on a type of skin cancer known as cutaneous squamous cell carcinoma (CSCC). The aim of the study is to see if cemiplimab or cemiplimab in combination with fianlimab can eliminate or reduce the number of living cancer cells in tumor(s) if taken before surgery. The study is looking at several other research questions, including: - Whether taking cemiplimab or cemiplimab in combination with fianlimab before surgery may make it possible to have a less extensive surgery or a different treatment plan after surgery - Whether taking cemiplimab or cemiplimab in combination with fianlimab before surgery may make the cancer less likely to come back after surgery - What side effects may happen from taking the cemiplimab or cemiplimab in combination with fianlimab - How much of the cemiplimab or cemiplimab in combination with fianlimab is in the blood at different times - Whether the body makes antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects)
Status | Not yet recruiting |
Enrollment | 140 |
Est. completion date | May 6, 2030 |
Est. primary completion date | June 8, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: 1. Stage III/IV (M0) CSCC, for which surgery would be recommended in routine clinical practice 2. Tumor biopsy is required during screening period as described in the protocol 3. Participant is willing to undergo delayed surgery 4. At least 1 lesion that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 6. Adequate organ and bone marrow function as described in the protocol Key Exclusion Criteria: 1. Stage I or II CSCC 2. Anogenital, penile, vermilion lip CSCC 3. CSCC bone invasion 4. Solid malignancy within 5 years of the projected enrollment date, or hematologic malignancy as described in the protocol 5. Prior radiation therapy for CSCC 6. Myocardial infarction within 6 months of enrollment, or history of myocarditis. 7. Prior treatment with anti-cancer systemic therapy within the last 3 years prior to projected enrollment date as described in the protocol Note: Other protocol-defined Inclusion/Exclusion Criteria apply |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Regeneron Pharmaceuticals |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pathological complete response (pCR) rate by blinded independent pathological review (BIPR) | Up to 100 days | ||
Secondary | pCR rate by local pathological review | Up to 100 days | ||
Secondary | Major pathological response (MPR) | Up to 100 days | ||
Secondary | Event-free survival (EFS) | Up to 3 years | ||
Secondary | Disease free survival (DFS) | Up to 3 years | ||
Secondary | Objective response rate (ORR) prior to surgery | Up to 100 days | ||
Secondary | Overall survival (OS) | Up to 3 years | ||
Secondary | Occurrence of treatment-emergent adverse events (TEAEs) | Up to 3 years | ||
Secondary | Occurrence of immune-mediated adverse events (imAEs) | Up to 3 years | ||
Secondary | Occurrence of treatment-related TEAEs | Up to 3 years | ||
Secondary | Occurrence of adverse event of special interest (AESI) | Up to 3 years | ||
Secondary | Occurrence of treatment-emergent serious adverse events (SAEs) | Up to 3 years | ||
Secondary | Occurrence of laboratory abnormalities | Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 | Up to 3 years | |
Secondary | Occurrence of death due to TEAE | Up to 3 years | ||
Secondary | Occurrence of interruption of study drug(s) due to TEAEs | Up to 3 years | ||
Secondary | Occurrence of discontinuation of study drug(s) due to TEAEs | Up to 3 years | ||
Secondary | Occurrence of cancellation of surgery due to TEAE | Up to 100 days | ||
Secondary | Occurrence of delay to surgery due to TEAE | Up to 100 days | ||
Secondary | Concentrations of cemiplimab in serum | Up to 3 years | ||
Secondary | Concentrations of fianlimab in serum | Up to 3 years | ||
Secondary | Concentrations of other experimental agents (as applicable) in serum | Up to 3 years | ||
Secondary | Incidence of anti-drug antibodies (ADA) to cemiplimab | Up to 3 years | ||
Secondary | Incidence of ADA to fianlimab | Up to 3 years | ||
Secondary | Incidence of ADA to other experimental agents (as applicable) | Up to 3 years | ||
Secondary | Titer of ADA to cemiplimab | Up to 3 years | ||
Secondary | Titer of ADA to fianlimab | Up to 3 years | ||
Secondary | Titer of ADA to other experimental agents (as applicable) | Up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT03212404 -
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
|
Phase 1 | |
Terminated |
NCT04502888 -
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
|
Phase 1 | |
Recruiting |
NCT05377905 -
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05888844 -
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT04050436 -
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
|
Phase 2 | |
Recruiting |
NCT05574101 -
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
|
Phase 2 | |
Completed |
NCT04616196 -
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05108090 -
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
|
N/A | |
Recruiting |
NCT06090266 -
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT04975152 -
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
|
Phase 1 | |
Completed |
NCT01500954 -
Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma
|
N/A | |
Suspended |
NCT04916002 -
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04339062 -
Cemiplimab in AlloSCT/SOT Recipients With CSCC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05565417 -
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
|
Phase 1/Phase 2 | |
Recruiting |
NCT04664582 -
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
|
N/A | |
Terminated |
NCT04596033 -
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
|
Phase 1 | |
Active, not recruiting |
NCT06046625 -
Needs and Preferences of Patients With Head-neck Cutaneous SCC
|
||
Recruiting |
NCT05859074 -
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
|
Phase 1 |